Teligent Inc. (TLGT) and Entera Bio Ltd. (NASDAQ:ENTX) Comparing side by side

Teligent Inc. (NASDAQ:TLGT) and Entera Bio Ltd. (NASDAQ:ENTX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Teligent Inc. 70.90M 1.19 27.99M -0.38 0.00
Entera Bio Ltd. N/A 0.00 11.43M -0.92 0.00

In table 1 we can see Teligent Inc. and Entera Bio Ltd.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Teligent Inc. -39.48% -47.7% -11.1%
Entera Bio Ltd. 0.00% 0% 0%


The Current Ratio of Teligent Inc. is 2.8 while its Quick Ratio stands at 1.8. The Current Ratio of rival Entera Bio Ltd. is 3.7 and its Quick Ratio is has 3.7. Entera Bio Ltd. is better equipped to clear short and long-term obligations than Teligent Inc.

Insider & Institutional Ownership

Roughly 86.8% of Teligent Inc. shares are held by institutional investors while 6.7% of Entera Bio Ltd. are owned by institutional investors. Insiders held roughly 0.2% of Teligent Inc.’s shares. Insiders Competitively, held 36.01% of Entera Bio Ltd. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Teligent Inc. -19.9% -51.9% -57.58% -48.76% -56% -54.55%
Entera Bio Ltd. 3.58% -2.14% 19.61% 0% 0% -12.58%

For the past year Teligent Inc. was more bearish than Entera Bio Ltd.


Entera Bio Ltd. beats on 6 of the 9 factors Teligent Inc.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The companyÂ’s products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.